PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort
ER-low/HER2-negative tumours had a high rate of pCR after the KEYNOTE-522 regimen. Our results suggest that patients with ER-low HER2-negative BC should be treated as ER-null/HER2-negative BC in the neoadjuvant setting to maximise pCR.
Authors
- Audrey Mailliez (ORCID: https://orcid.org/0000-0002-0475-8631)
- François‐Clément Bidard (ORCID: https://orcid.org/0000-0001-5932-8949)
- Alison Johnson (ORCID: https://orcid.org/0000-0002-4886-9544)
- Fatima Cherifi (ORCID: https://orcid.org/0000-0002-1399-8661)
- C. Bousrih
- Alexandre de Nonneville (ORCID: https://orcid.org/0000-0001-6710-8284)
- Quiterie Aussedat
- Jean‐Sébastien Frenel (ORCID: https://orcid.org/0000-0002-5273-0561)
- E Bastien
- B Mery
- Caroline Bailleux (ORCID: https://orcid.org/0000-0003-4188-3367)
- Florence Dalenc (ORCID: https://orcid.org/0000-0002-9854-4182)
- Sylvain Ladoire (ORCID: https://orcid.org/0000-0002-0331-9194)
- George Emile (ORCID: https://orcid.org/0000-0002-8505-4387)
- Mathieu Kuentz
- Serge Aho (ORCID: https://orcid.org/0000-0001-7590-8644)
- Luc Cabel (ORCID: https://orcid.org/0000-0001-5515-9180)
- M. Alexandre (ORCID: https://orcid.org/0000-0003-0155-9239)
- M. Debled
- Marianne Leheurteur
- Elsa Volant
- François Christy (ORCID: https://orcid.org/0009-0009-1519-8260)
- Joana Ribeiro (ORCID: https://orcid.org/0000-0001-7947-672X)
- A. Glenet
- L. Benistant
- Delphine Loirat
Institutions
- Institut Gustave Roussy (FR)
- Institut de Cancérologie Strasbourg (FR)
- Centre Georges François Leclerc (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Centre François Baclesse (LU)
- Centre Léon Bérard (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Centre Eugène Marquis (FR)
- Centre François Baclesse (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Centre Oscar Lambret (FR)
- Institut Bergonié (FR)
- Laboratoire National Henri Becquerel (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Institut Paoli-Calmettes (FR)
- Centre Antoine Lacassagne (FR)
- Institut Curie (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105907
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- AstraZeneca
- Chugai Pharmaceutical